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troke Prevention
ersus Bleeding Risk
n Atrial Fibrillation
Clinical Dilemma*
tefan H. Hohnloser, MD
rankfurt, Germany
trial fibrillation (AF) is the most common serious chronic
eart rhythm disorder, with an estimated prevalence in the
eneral population of approximately 1% (1). The arrhyth-
ia affects approximately 2.2 million persons in the U.S.
nd 4.5 million in the European Union. Because of the
dvancing age of the population, the prevalence of AF is
ikely to increase even further (2). Atrial fibrillation is
ssociated with major morbidity and mortality, particularly
ue to thromboembolic complications. In patients older
han 80 years of age, approximately 15% of all strokes are
ttributable to AF. Moreover, AF-related strokes are known
o be associated with higher mortality and more disability
han strokes of other origins (3).
See page 173
Solid evidence exists that anticoagulation therapy with
itamin K antagonists reduces AF-related stroke risk by
wo-thirds compared to placebo (relative risk reduction
RRR]: 62%, 95% confidence interval [CI]: 48% to 72%),
hereas aspirin decreases stroke risk only by 22% (RRR:
2%, 95% CI: 3% to 38%) (4). Vitamin K antagonists are
learly superior even in patients 75 years of age, as
emonstrated in the BAFTA (Birmingham Atrial Fibrilla-
ion Treatment of the Aged) study (5). Vitamin K antago-
ists also reduce the risk of stroke by one-third compared
ith the combination of acetylsalicylic acid and clopidogrel,
s recently shown in the ACTIVE W (Atrial Fibrillation
lopidogrel Trial With Irbesartan for Prevention of Vas-
ular Events) trial (RRR: 42%, 95% CI: 19% to 58%) (6).
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itamin K antagonists is hemorrhage, with intracranial
leeding representing the most feared complication. Vita-
in K antagonists compared with acetylsalicylic acid signif-
cantly increase the risk of major bleeding (2.2 vs. 1.3 events
er 100 patient-years; p  0.02) (7). Vitamin K antagonists
ave numerous other limitations, such as slow onset and
ffset kinetics and a narrow therapeutic window, and their
etabolism is affected by diet, drugs, and genetic polymor-
hisms. However, the fear of iatrogenic hemorrhage is
lmost certainly one of the most important reasons why
hysicians do not prescribe warfarin for a substantial num-
er of AF patients who are likely to benefit from it (8).
In contrast to current guideline recommendations, con-
emporary surveys of practice patterns, for instance, stem-
ing from administrative databases, demonstrate that 40%
o 50% of patients with AF who are at substantial risk for
troke are not treated with vitamin K antagonists (8–13). A
ecent study from the Canadian Stroke Network, for in-
tance, showed that among 597 patients with known AF
ho had no contraindications for warfarin and who were
dmitted to hospital with acute ischemic stroke, only 10%
eceived therapeutic anticoagulation (international normal-
zed ratio [INR]2.0) at the time of stroke admission (14).
ven among a subset of AF patients with a prior history of
troke or transient ischemic attack, only 18% were taking
arfarin with a therapeutic INR at the time of admission for
troke. When anticoagulation therapy with vitamin K an-
agonists is applied, the quality of anticoagulation treatment
s less than optimal. A recent survey from the U.S. found
hat, on average, patients only spent a mean of 55% of their
ime in the therapeutic INR range (15). There were signif-
cant differences in quality of therapy, with standard com-
unity care giving 11% less time in the therapeutic range
ompared to anticoagulation clinic services. Similarly, the
iscontinuation rate of warfarin is high, particularly by
lderly AF patients. A recent study reported that within the
rst year of therapy, 26% of patients 80 years of age
topped taking warfarin. Perceived safety issues, particularly
oncerns about bleeding, accounted for 81% of them (16).
ven among patients who were prescribed vitamin K
ntagonists for secondary prevention after having suffered a
rst AF-related stroke, there was a high discontinuation
ate of warfarin therapy, with only 45% of patients continu-
ng on this treatment after 2 years (17). Thus, anticoagula-
ion therapy is underused, is suboptimally applied, and is
ften inappropriately discontinued. All of this is driven for
good part by the perceived bleeding risk associated with
itamin K antagonists therapy.
Both the risk for stroke and the risk for bleeding are not
omogenous in AF. Accordingly, there have been numerous
ttempts to stratify AF patients for their individual risk. The
HADS2 (Cardiac failure, Hypertension, Age 75 years,
iabetes, Stroke, the latter scoring 2 points) score has
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Bleeding Risk in Atrial Fibrillation January 11, 2011:181–3volved over recent years as being an easily applicable, useful
ool to subdivide patients into those at low, intermediate, or
igh risk for AF-related stroke (18). However, it has been
ncreasingly recognized that many risk factors for stroke are
lso associated with a higher risk for anticoagulation-
ssociated hemorrhage. In fact, bleeding risk increases with
ncreasing CHADS2 scores (17). Therefore, attempts have
een made to develop separate scoring systems to identify
linical risk factors associated with incremental risk for
emorrhage (19–22). However, some of these risk scores
mploy complex scoring systems (19,22) that significantly
imit their clinical applicability. Others have not been
horoughly validated in AF populations but rather in gen-
ral anticoagulated populations, likely with fewer comor-
idities than observed in AF patients (21,22). As a conse-
uence, none of these risk scores has gained widespread
cceptance in clinical practice.
In this issue of the Journal, Lip et al. (23) present a
horough validation of a new risk score, called HAS-BLED
an acronym for hypertension, abnormal renal/liver func-
ion, stroke, bleeding history or predisposition, labile INR,
lderly [65 years of age], drugs/alcohol concomitantly),
or predicting bleeding risk in anticoagulated AF patients.
his score has been recently derived from an European AF
opulation (24) and is now validated using a database
eparate from that in which it was developed. In addition,
he authors performed a head-to-head comparison with
revious risk prediction scores. Data from 2 large random-
zed phase III trials of ximelagratan versus warfarin for
troke prevention in AF comprising 11,000 patient-years
f oral anticoagulation exposure were utilized. The valida-
ion of the HAS-BLED score in an AF population different
rom the inception population confirmed the predictive
ower of this score. Upon comparison with previous risk
cores, evidence indicated that the HAS-BLED score may
e associated with better predictive accuracy than its prede-
essors: The c statistics for this score were somewhat higher
han those of previous scores, although they were not
arkedly higher. Importantly, hazard ratios for distinction
mong low, moderate, and high bleeding risks were greater
or the HAS-BLED score than for any other scoring
ystem. Finally, upon multivariate Cox regression analysis,
he new score added significantly to those models that
lready incorporated the old models. In contrast, none of
he older models significantly contributed when inserted in
model already incorporating the HAS-BLED score. For
hese reasons, the new score may indeed prove to be an
mportant clinical tool to assess bleeding risk in AF patients,
nd the authors should be congratulated for their careful
nalyses.
As potential limitations, it should be mentioned that data
rom randomized clinical trials do not necessarily reflect
aily clinical practice. Because the HAS-BLED score has
een validated using trial data, it remains to be seen how itill perform in daily routine practice. Furthermore, new
ntithrombotic agents, such as dabigatran (25) or apixaban
26), are likely to be approved for clinical use. Whether the
leeding risk scores developed from data on patients receiv-
ng vitamin K antagonists apply to new anticoagulants that
ay have lesser bleeding risk (particularly with respect to
ntracranial bleeds [25]) remains to be seen. More efforts are
learly needed for better prediction of individual stroke and
leeding risk, with subsequent improved tailoring of therapy
o the patients who will derive benefit from anticoagulation
herapy. The development of the HAS-BLED score may
urn out to be an important step in that direction.
eprint requests and correspondence: Dr. Stefan H. Hohnloser,
epartment of Cardiology, Division of Clinical Electrophysiology,
. W. Goethe University, Theodor Stern Kai 7, Frankfurt 60590,
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